In a major milestone for the biopharmaceutical sector, Minaris Advanced Therapies has inaugurated its state-of-the-art GMP manufacturing facility in Taufkirchen, Munich, bolstering its role as a key global partner in the cell and gene therapy supply chain. This strategic expansion underscores Minaris’ commitment to supporting the growing demand for advanced therapies with scalable, high-quality, and globally integrated solutions.
Strengthening Europe’s Therapeutic Manufacturing Capabilities
The new facility positions Minaris as a central player in Europe’s biotech manufacturing ecosystem. Strategically located near the Munich International Airport, the plant ensures logistical efficiency, enabling timely delivery and smooth technology transfer for commercial-scale cell and gene therapies across the continent.
With over a decade of manufacturing expertise, Minaris consolidates its process development, quality control, and legacy production into one unified site, advancing its mission to deliver therapies from concept to commercialization with speed and precision.
Cutting-Edge Infrastructure for Advanced Therapies
The Munich facility offers a future-proofed, flexible manufacturing environment:
- Six Grade B/A cleanrooms for aseptic processing
- Convertible Grade C cleanroom for closed systems and bioreactors
- 224 m² of expandable space for future growth
- Independent HVAC systems for parallel production streams
- Integrated cryopreservation and storage facilities
- Dedicated process development and QC labs
- Enhanced alarm and safety protocols
This advanced infrastructure enables high-throughput, multi-product operations, reducing downtime and accelerating production cycles in compliance with international regulatory standards.
Impact on Global Manufacturing Strategy
“The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally,” said Dr. Orla Cloak, Chief Executive Officer of Minaris Advanced Therapies. “It enhances our European footprint and enhances our ability to meet client needs with speed, quality, and scalability.”
“This facility embodies our shared vision for the future of cell and gene therapy manufacturing—scalable, flexible, and globally integrated,” said Iain Baird, Chairman of the Board, Minaris Advanced Therapies. “The seamless transition into this new facility is a testament to the dedication of our team in Germany and the commitment Minaris Advanced Therapies has to bring long-term value to clients and patients worldwide.”
The ribbon-cutting event on July 31 showcased the leadership’s vision and the dedication of the German team, reflecting Minaris’ long-term commitment to biopharmaceutical innovation and operational excellence.
Broader Implications for the Healthcare Industry
As a contract development and manufacturing organization (CDMO), Minaris plays an instrumental role in accelerating therapy developers’ timelines—from clinical trial support to full-scale commercial deployment. With over 7,500 GMP batches released and a 650,000 square foot network across the U.S., Europe, and Asia, Minaris is positioned as a leader in advanced therapy manufacturing.
Its parent company, Altaris, continues to back healthcare innovation with $10 billion in equity capital focused exclusively on transforming and growing healthcare companies.
Strategic Significance
This expansion is more than operational—it is a strategic move to meet the surging global demand for cell and gene therapies, especially in the European market. The Munich facility serves as a cornerstone in Minaris’ strategy to offer end-to-end solutions, from early development to commercial launch, thereby empowering biotechnology firms with seamless scalability.
